RETRACTED ARTICLE: Partially hydrolysed, prebiotic supplemented whey formula for the prevention of allergic manifestations in high risk infants: a multicentre double-blind randomised controlled trial

Controlled Trial ◽

Double Blind ◽

Retracted Article ◽

High Risk Infants ◽

Randomised Controlled ◽

Allergic Manifestations

Retraction Note to: Partially hydrolysed, prebiotic supplemented whey formula for the prevention of allergic manifestations in high risk infants: a multicentre double-blind randomised controlled trial

Clinical and Translational Allergy ◽

10.1186/s13601-020-00356-5 ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Robert Boyle ◽

Nick Brown ◽

Wen Chin Chiang ◽

Chua Mei Chien ◽

Michael Gold ◽

...

Keyword(s):

High Risk ◽

Controlled Trial ◽

Double Blind ◽

High Risk Infants ◽

Randomised Controlled ◽

Allergic Manifestations

An amendment to this paper has been published and can be accessed via the original article.

Investigating the effectiveness of the Mediterranean diet in pregnant women for the primary prevention of asthma and allergy in high-risk infants: protocol for a pilot randomised controlled trial

Trials ◽

10.1186/1745-6215-14-173 ◽

2013 ◽

Vol 14 (1) ◽

pp. 173 ◽

Cited By ~ 13

Author(s):

Dean A Sewell ◽

Victoria S Hammersley ◽

Graham Devereux ◽

Ann Robertson ◽

Andrew Stoddart ◽

...

Keyword(s):

Primary Prevention ◽

High Risk ◽

Pregnant Women ◽

Mediterranean Diet ◽

Controlled Trial ◽

Pilot Randomised Controlled Trial ◽

Asthma And Allergy ◽

High Risk Infants ◽

A 52 week double blind randomised controlled trial comparing the effect of rosiglitazone versus placebo on the prevention of progression of atherosclerosis in high risk patients without diabetes

http://isrctn.org/> ◽

10.1186/isrctn54951661 ◽

2013 ◽

Author(s):

R. Alizadeh Dehnavi

Keyword(s):

High Risk ◽

Controlled Trial ◽

Double Blind ◽

High Risk Patients ◽

Risk Patients ◽

Randomised Controlled ◽

Progression Of Atherosclerosis

Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomised controlled trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(19)30337-1 ◽

2020 ◽

Vol 5 (2) ◽

pp. 132-141 ◽

Cited By ~ 1

Author(s):

Evan L Fogel ◽

Glen A Lehman ◽

Paul Tarnasky ◽

Gregory A Cote ◽

Suzette E Schmidt ◽

...

Keyword(s):

High Risk ◽

Endoscopic Retrograde Cholangiopancreatography ◽

Dose Escalation ◽

Controlled Trial ◽

Endoscopic Retrograde ◽

Double Blind ◽

High Risk Patients ◽

Risk Patients ◽

ATTRITION RATES AND REASONS IN A DOUBLE-BLIND RANDOMISED CONTROLLED TRIAL IN AN ULTRA-HIGH RISK COHORT

Schizophrenia Research ◽

10.1016/s0920-9964(08)70474-2 ◽

2008 ◽

Vol 102 (1-3) ◽

pp. 156

Author(s):

Magenta Simmons ◽

Barnaby Nelson ◽

Alison Yung ◽

Lisa Phillips ◽

Shona Francey ◽

...

Keyword(s):

High Risk ◽

Controlled Trial ◽

Double Blind ◽

Attrition Rates ◽

Ultra High Risk ◽

Randomised Controlled ◽

High Risk Cohort

A MULTICENTRE DOUBLE-BLIND RANDOMISED CONTROLLED TRIAL TO ASSESS THE CLINICAL- AND COST-EFFECTIVENESS OF FACET-JOINT INJECTIONS IN PATIENTS WITH NON-SPECIFIC LOW BACK PAIN: A FEASIBILITY STUDY

10.26226/morressier.59ad4811d462b80290b53a8a ◽

2017 ◽

Author(s):

Ahmad Alia

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Cost Effectiveness ◽

Facet Joint ◽

Controlled Trial ◽

Low Back ◽

Double Blind ◽

Randomised Controlled ◽

Joint Injections

Faculty Opinions recommendation of TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1058963.510919 ◽

2007 ◽

Author(s):

Pascal Derkinderen

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Controlled Trial ◽

Double Blind ◽

Faculty Opinions recommendation of Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3447957.3171054 ◽

2010 ◽

Author(s):

Takahiko Nakagawa

Keyword(s):

High Risk ◽

Cardiovascular Events ◽

Controlled Trial ◽

Secondary Analysis ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Combination Therapies ◽

Dose Combination ◽

Faculty Opinions recommendation of The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717955094.793462652 ◽

2012 ◽

Author(s):

Chim Lang

Keyword(s):

Heart Failure ◽

Controlled Trial ◽

Preserved Ejection Fraction ◽

Phase 2 ◽

Angiotensin Receptor ◽

Double Blind ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor ◽

Faculty Opinions recommendation of Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718482844.793498728 ◽

2014 ◽

Author(s):

Carlos Seas ◽

Joel Lopez

Keyword(s):

Controlled Trial ◽

Double Blind ◽